SAGE THERAPEUTICS INC's ticker is SAGE and the CUSIP is 78667J108. A total of 254 filers reported holding SAGE THERAPEUTICS INC in Q4 2018. The put-call ratio across all filers is 0.67 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,432,556 | -55.8% | 118,200 | +1.0% | 0.00% | -50.0% |
| Q2 2023 | $5,501,340 | +13.5% | 117,000 | +1.3% | 0.00% | +33.3% |
| Q1 2023 | $4,846,380 | -1.7% | 115,500 | -10.6% | 0.00% | -25.0% |
| Q4 2022 | $4,927,688 | -0.2% | 129,200 | +2.5% | 0.00% | 0.0% |
| Q3 2022 | $4,938,000 | +22.0% | 126,100 | +0.6% | 0.00% | +33.3% |
| Q2 2022 | $4,047,000 | -2.4% | 125,300 | 0.0% | 0.00% | +50.0% |
| Q1 2022 | $4,147,000 | -16.2% | 125,300 | +7.7% | 0.00% | -33.3% |
| Q4 2021 | $4,947,000 | -4.0% | 116,300 | 0.0% | 0.00% | 0.0% |
| Q3 2021 | $5,153,000 | -21.7% | 116,300 | +0.4% | 0.00% | -25.0% |
| Q2 2021 | $6,579,000 | -26.1% | 115,800 | -2.7% | 0.00% | -33.3% |
| Q1 2021 | $8,907,000 | -12.4% | 119,000 | +1.3% | 0.01% | -14.3% |
| Q4 2020 | $10,165,000 | +41.3% | 117,500 | -0.2% | 0.01% | +16.7% |
| Q3 2020 | $7,194,000 | +49.4% | 117,700 | +1.6% | 0.01% | +50.0% |
| Q2 2020 | $4,815,000 | +66.8% | 115,800 | +15.2% | 0.00% | +33.3% |
| Q1 2020 | $2,886,000 | -59.5% | 100,500 | +1.7% | 0.00% | -57.1% |
| Q4 2019 | $7,132,000 | -47.2% | 98,800 | +2.6% | 0.01% | -50.0% |
| Q3 2019 | $13,510,000 | -22.2% | 96,300 | +1.6% | 0.01% | -26.3% |
| Q2 2019 | $17,357,000 | +27.8% | 94,800 | +11.0% | 0.02% | +26.7% |
| Q1 2019 | $13,583,000 | +71.9% | 85,400 | +3.5% | 0.02% | +50.0% |
| Q4 2018 | $7,903,000 | -31.0% | 82,500 | +1.7% | 0.01% | -23.1% |
| Q3 2018 | $11,455,000 | -8.6% | 81,100 | +1.2% | 0.01% | -7.1% |
| Q2 2018 | $12,538,000 | -2.0% | 80,100 | +0.9% | 0.01% | -12.5% |
| Q1 2018 | $12,789,000 | +17.1% | 79,400 | +19.8% | 0.02% | +33.3% |
| Q4 2017 | $10,920,000 | +228.8% | 66,300 | +24.4% | 0.01% | +200.0% |
| Q3 2017 | $3,321,000 | -21.8% | 53,300 | 0.0% | 0.00% | -20.0% |
| Q2 2017 | $4,245,000 | +14.6% | 53,300 | +2.3% | 0.01% | 0.0% |
| Q1 2017 | $3,703,000 | +43.6% | 52,100 | +3.2% | 0.01% | +25.0% |
| Q4 2016 | $2,579,000 | +10.9% | 50,500 | 0.0% | 0.00% | 0.0% |
| Q3 2016 | $2,326,000 | +89.7% | 50,500 | +24.1% | 0.00% | +100.0% |
| Q2 2016 | $1,226,000 | +19.7% | 40,700 | +23.0% | 0.00% | 0.0% |
| Q1 2016 | $1,024,000 | +0.4% | 33,100 | +89.1% | 0.00% | 0.0% |
| Q4 2015 | $1,020,000 | +37.7% | 17,500 | 0.0% | 0.00% | 0.0% |
| Q3 2015 | $741,000 | -32.3% | 17,500 | +16.7% | 0.00% | -33.3% |
| Q2 2015 | $1,095,000 | +296.7% | 15,000 | +172.7% | 0.00% | +200.0% |
| Q1 2015 | $276,000 | +37.3% | 5,500 | 0.0% | 0.00% | 0.0% |
| Q4 2014 | $201,000 | – | 5,500 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| GREAT POINT PARTNERS LLC | 1,966,688 | $120,204,000 | 10.81% |
| Integral Health Asset Management, LLC | 230,000 | $14,058,000 | 4.30% |
| Asymmetry Capital Management, L.P. | 102,462 | $6,262,000 | 4.02% |
| ACUTA CAPITAL PARTNERS, LLC | 225,000 | $13,752,000 | 3.74% |
| DAFNA Capital Management LLC | 158,306 | $9,676,000 | 3.14% |
| Bain Capital Life Sciences Investors, LLC | 499,100 | $30,505,000 | 2.84% |
| Boxer Capital, LLC | 1,094,000 | $66,865,000 | 2.31% |
| Palo Alto Investors LP | 590,200 | $36,073,000 | 1.98% |
| Logos Global Management LP | 250,000 | $15,280,000 | 1.96% |
| Bellevue Group AG | 1,579,504 | $96,539,000 | 1.33% |